Catalyst overview
Research summary
This catalyst tracks a Phase 3 data readout for Survodutide (GLP-1/Glucagon Agonist) in Obesity. The expected timing is based on the latest available company guidance and may change.
12/11/25:- Report data throughout 2026, multiple readouts planned.
Verification
Confirm timing and program details against the company announcement or filing.